Search

Your search keyword '"de Vries, Rory D"' showing total 506 results
Start Over Author "de Vries, Rory D"
506 results on '"de Vries, Rory D"'

4. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M., Tan, Ngoc H., Rietdijk, Wim J. R., Geers, Daryl, Sablerolles, Roos S. G., Bogers, Susanne, van Dijk, Laura L. A., Gommers, Lennert, van Leeuwen, Leanne P. M., Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Dalm, Virgil A. S. H., Lafeber, Melvin, Kootstra, Neeltje A., Huckriede, Anke L. W., Haagmans, Bart L., van Baarle, Debbie, Koopmans, Marion P. G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

5. Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients

Author

den Hartog, Yvette, Malahe, S. Reshwan K., Rietdijk, Wim J. R., Dieterich, Marjolein, Gommers, Lennert, van Baarle, Debbie, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Bemelman, Frederike J., Kho, Marcia M. L., GeurtsvanKessel, Corine H., Koopmans, Marion P. G., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, Reinders, Marlies E. J., Baan, Carla C., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

6. Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial

Author

Malahe, S. Reshwan K., den Hartog, Yvette, Rietdijk, Wim J. R., van Baarle, Debbie, de Kuiper, Ronella, Reijerkerk, Derek, Ras, Alicia M., Geers, Daryl, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Imhof, Céline, Frölke, Sophie C., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan F., GeurtsvanKessel, Corine H., Kho, Marcia M. L., de Vries, Rory D., Reinders, Marlies E. J., Baan, Carla C., Abrahams, Alferso C., Baas, Marije C., Bouwmans, Pim, ten Dam, Marc A. G. J., Gommers, Lennert, Standaar, Dorien, van der Heiden, Marieke, Adema, Yvonne M. R., Boer-Verschragen, Marieken J, Mattheussens, Wouter B., Philipsen, Ria H. L. A., van Mourik, Djenolan, Bogers, Susanne, van Dijk, Laura L. A., Rots, Nynke, Hemmelder, Marc H., and de Vries, Aiko P. J.

Published
2024
Full Text
View/download PDF

7. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants

Author

Fryer, Holly A., Geers, Daryl, Gommers, Lennert, Zaeck, Luca M., Tan, Ngoc H., Jones-Freeman, Bernadette, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Hogarth, P. Mark, Koopmans, Marion P.G., GeurtsvanKessel, Corine H., O’Hehir, Robyn E., van der Kuy, P. Hugo M., de Vries, Rory D., and van Zelm, Menno C.

Published
2024
Full Text
View/download PDF

8. Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study

Author

De Vos, Elise, Van Gestel, Liesbeth, Brosius, Isabel, Kenyon, Chris, Vuylsteke, Bea, De Baetselier, Irith, Mariën, Joachim, Bangwen, Eugene, Couvreur, Simon, Lecompte, Amaryl, Van Beckhoven, Dominique, Hoorelbeke, Bart, Verstrepen, Babs E., Zaeck, Luca M., de Vries, Rory D., Geurts van Kessel, Corine H., Hens, Niel, Ariën, Kevin K., Vercauteren, Koen, Van Esbroek, Marjan, Van Dijck, Christophe, and Liesenborghs, Laurens

Published
2024
Full Text
View/download PDF

11. Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses

Author

den Hartog, Yvette, Malahe, S. Reshwan K., Rietdijk, Wim J. R., Dieterich, Marjolein, Gommers, Lennert, Geers, Daryl, Bogers, Susanne, van Baarle, Debbie, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M. L., Reinders, Marlies E. J., de Vries, Rory D., and Baan, Carla C.

Published
2023
Full Text
View/download PDF

12. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients

Author

Abrahams, Alferso C., Baas, Marije C., Mattheussens, Wouter B., Philipsen, Ria H.L.A., Bouwmans, Pim, Hemmelder, Marc H., ten Dam, Marc A.G.J., Gommers, Lennert, Mourik, Djenolan van, Bogers, Susanne, van Dijk, Laura L.A., Standaar, Dorien, der Heiden, Marieke van, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Rots, Nynke, de Vries, Aiko P.J., Malahe, S. Reshwan K., Hartog, Yvette den, Rietdijk, Wim J.R., van Baarle, Debbie, de Kuiper, Ronella, Reijerkerk, Derek, Ras, Alicia M., Geers, Daryl, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B.M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M.L., de Vries, Rory D., Reinders, Marlies E.J., and Baan, Carla C.

Published
2023
Full Text
View/download PDF

13. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Author

Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, and van der Kuy, P Hugo M

Published
2023
Full Text
View/download PDF

14. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

Author

Zaeck, Luca M., Lamers, Mart M., Verstrepen, Babs E., Bestebroer, Theo M., van Royen, Martin E., Götz, Hannelore, Shamier, Marc C., van Leeuwen, Leanne P. M., Schmitz, Katharina S., Alblas, Kimberley, van Efferen, Suzanne, Bogers, Susanne, Scherbeijn, Sandra, Rimmelzwaan, Guus F., van Gorp, Eric C. M., Koopmans, Marion P. G., Haagmans, Bart L., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2023
Full Text
View/download PDF

15. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial

Author

Abrahams, Alferso C., Baas, Marije C., Bouwmans, Pim, ten Dam, Marc A.G.J., Gommers, Lennert, Standaar, Dorien, van der Heiden, Marieke, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Mattheussens, Wouter B., Philipsen, Ria H.L.A., van Mourik, Djenolan, Bogers, Susanne, van Dijk, Laura L.A., Rots, Nynke, Smits, Gaby, Kuijer, Marjan, Hemmelder, Marc H., Kho, Marcia M L, Messchendorp, A Lianne, Frölke, Sophie C, Imhof, Celine, Koomen, Vera JCH, Malahe, S Reshwan K, Vart, Priya, Geers, Daryl, de Vries, Rory D, GeurtsvanKessel, Corine H, Baan, Carla C, van der Molen, Renate G, Diavatopoulos, Dimitri A, Remmerswaal, Ester B M, van Baarle, Debbie, van Binnendijk, Rob, den Hartog, Gerco, de Vries, Aiko P J, Gansevoort, Ron T, Bemelman, Frederike J, Reinders, Marlies E J, Sanders, Jan-Stephan F, and Hilbrands, Luuk B

Published
2023
Full Text
View/download PDF

16. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Author

Geers, Daryl, Sablerolles, Roos S.G., van Baarle, Debbie, Kootstra, Neeltje A., Rietdijk, Wim J.R., Schmitz, Katharina S., Gommers, Lennert, Bogers, Susanne, Nieuwkoop, Nella J., van Dijk, Laura L.A., van Haren, Eva, Lafeber, Melvin, Dalm, Virgil A.S.H., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Huckriede, Anke L.W., Sette, Alessandro, Grifoni, Alba, de Swart, Rik L., Koopmans, Marion P.G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2023
Full Text
View/download PDF

17. High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients

Author

Hoek, Rogier AS, Verschuuren, Erik AM, de Vries, Rory D, Vonk, Judith M., van Baarle, Debbie, van der Heiden, Marieke, van Gemert, Johanna P, Gore, Edmund J, Niesters, Hubert GM, Erasmus, Michiel, Hellemons, Merel E., Scherbeijn, Sandra MJ, Wijbenga, Nynke, Mahtab, Edris A.F., GeurtsvanKessel, Corine H., and Buter, Coretta Van Leer

Published
2022
Full Text
View/download PDF

18. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity

Author

van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S.F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A.S.H.

Published
2022
Full Text
View/download PDF

22. SARS-CoV-2 Spike-specific IFN-γ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Author

Imhof, Céline, Messchendorp, A. Lianne, van der Heiden, Marieke, Baan, Carla C., van der Molen, Renate G., Remmerswaal, Ester B. M., de Vries, Rory D., Diavatopoulos, Dimitri A., Boerma, Annemarie, Bakker, Femke J., Oosterhout, Emily, Bemelman, Frederike J., Hilbrands, Luuk B., Reinders, Marlies E. J., Gansevoort, Ron T., Sanders, Jan-Stephan, and van Baarle, Debbie

Published
2022
Full Text
View/download PDF

24. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome.

Author

Nouwen, Anouk E. M., Zaeck, Luca M., Schappin, Renske, Geers, Daryl, Gommers, Lennert, Bogers, Susanne, Dik, Willem A., Pasmans, Suzanne G. M. A., GeurtsvanKessel, Corine H., de Vries, Rory D., and Dalm, Virgil A. S. H.

Subjects
BOOSTER vaccines, VACCINE effectiveness, HAEMOPHILUS influenzae, STREPTOCOCCUS pneumoniae, POLYSACCHARIDES
Abstract

Background: Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency. Methods: Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls. Results: None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls. Conclusions: Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Scenarios of future mpox outbreaks among men who have sex with men: a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022

Author

Shamier, Marc C, primary, Zaeck, Luca M, additional, Götz, Hannelore M, additional, Vieyra, Bruno, additional, Verstrepen, Babs E, additional, Wijnans, Koen, additional, Welkers, Matthijs RA, additional, Hoornenborg, Elske, additional, van Cleef, Brigitte AGL, additional, van Royen, Martin E, additional, Jonas, Kai J, additional, Koopmans, Marion PG, additional, de Vries, Rory D, additional, van de Vijver, David AMC, additional, and GeurtsvanKessel, Corine H, additional

Published
2024
Full Text
View/download PDF

30. Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments

Author

Schmitz, Katharina S., primary, Handrejk, Kim, additional, Liepina, Lelde, additional, Bauer, Lisa, additional, Haas, Griffin D., additional, van Puijfelik, Fabiënne, additional, Veldhuis Kroeze, Edwin J. B., additional, Riekstina, Marta, additional, Strautmanis, Jurgis, additional, Cao, Huyen, additional, Verdijk, Robert M., additional, GeurtsvanKessel, Corine H., additional, van Boheemen, Sander, additional, van Riel, Debby, additional, Lee, Benhur, additional, Porotto, Matteo, additional, de Swart, Rik L., additional, and de Vries, Rory D., additional

Published
2024
Full Text
View/download PDF

33. Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., and Rokx, Casper

Subjects
Biological sciences
Abstract

Author(s): Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, Corine H. GeurtsvanKessel, Yvonne M. Mueller, Virgil A. S. H. Dalm, Grigorios Papageorgiou, Hanka Steggink, Alicja Gorska, Susanne Bogers, Jan G. [...]

Published
2023
Full Text
View/download PDF

34. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Author

Sanders, Jan-Stephan F., Bemelman, Frederike J., Messchendorp, A. Lianne, Baan, Carla C., van Baarle, Debbie, van Binnendijk, Rob, Diavatopoulos, Dimitri A., Frölke, Sophie C., Geers, Daryl, GeurtsvanKessel, Corine H., den Hartog, Gerco, van der Heiden, Marieke, Imhof, Celine, Kho, Marcia M. L., Koopmans, Marion P. G., Malahe, S. Reshwan K., Mattheussens, Wouter B., van der Molen, Renate, van Mourik, Djenolan, Remmerswaal, Ester B. M., Rots, Nynke, Vart, Priya, de Vries, Rory D., Gansevoort, Ron T., Hilbrands, Luuk B., and Reinders, Marlies E. J.

Published
2021
Full Text
View/download PDF

35. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity

Author

MS Nefrologie, Circulatory Health, Aguilar-Bretones, Muriel, den Hartog, Yvette, van Dijk, Laura L.A., Malahe, S. Reshwan K., Dieterich, Marjolein, Mora, Héctor Tejeda, Mueller, Yvonne M., Koopmans, Marion P.G., Reinders, Marlies E.J., Baan, Carla C., van Nierop, Gijsbert P., de Vries, Rory D., Abrahams, Alferso C., Baas, Marije C., Hemmelder, Marc H., Bouwmans, Pim, ten Dam, Marc A.G.J., Gommers, Lennert, de Vries, Aiko P.J., MS Nefrologie, Circulatory Health, Aguilar-Bretones, Muriel, den Hartog, Yvette, van Dijk, Laura L.A., Malahe, S. Reshwan K., Dieterich, Marjolein, Mora, Héctor Tejeda, Mueller, Yvonne M., Koopmans, Marion P.G., Reinders, Marlies E.J., Baan, Carla C., van Nierop, Gijsbert P., de Vries, Rory D., Abrahams, Alferso C., Baas, Marije C., Hemmelder, Marc H., Bouwmans, Pim, ten Dam, Marc A.G.J., Gommers, Lennert, and de Vries, Aiko P.J.

Published
2024

36. Potential determinants of the decline in mpox cases in Belgium:A behavioral, epidemiological and seroprevalence study

Author

De Vos, Elise, Van Gestel, Liesbeth, Brosius, Isabel, Kenyon, Chris, Vuylsteke, Bea, De Baetselier, Irith, Mariën, Joachim, Bangwen, Eugene, Couvreur, Simon, Lecompte, Amaryl, Van Beckhoven, Dominique, Hoorelbeke, Bart, Verstrepen, Babs E., Zaeck, Luca M., de Vries, Rory D., Geurts van Kessel, Corine H., Hens, Niel, Ariën, Kevin K., Vercauteren, Koen, Van Esbroek, Marjan, Van Dijck, Christophe, Liesenborghs, Laurens, De Vos, Elise, Van Gestel, Liesbeth, Brosius, Isabel, Kenyon, Chris, Vuylsteke, Bea, De Baetselier, Irith, Mariën, Joachim, Bangwen, Eugene, Couvreur, Simon, Lecompte, Amaryl, Van Beckhoven, Dominique, Hoorelbeke, Bart, Verstrepen, Babs E., Zaeck, Luca M., de Vries, Rory D., Geurts van Kessel, Corine H., Hens, Niel, Ariën, Kevin K., Vercauteren, Koen, Van Esbroek, Marjan, Van Dijck, Christophe, and Liesenborghs, Laurens

Abstract

Objectives: The 2022 mpox epidemic reached a peak in Belgium and the rest of Europe in July 2022, after which it unexpectedly subsided. This study investigates epidemiological, behavioral, and immunological factors behind the waning of the epidemic in Belgium. Methods: We investigated temporal evolutions in the characteristics and behavior of mpox patients using national surveillance data and data from a prospective registry of mpox patients in the Institute of Tropical Medicine (Antwerp). We studied behavioral changes in the population at risk using a survey among HIV-preexposure prophylaxis (PrEP) users. We determined the seroprevalence of anti-orthopoxvirus antibodies among HIV-PrEP users across four-time points in 2022. Results: Mpox patients diagnosed at the end of the epidemic had less sexual risk behavior compared to those diagnosed earlier: they engaged less in sex at mass events, had fewer sexual partners, and were less likely to belong to the sexual network's central group. Among HIV-PrEP users there were no notable changes in sexual behavior. Anti-orthopoxvirus seroprevalence did not notably increase before the start of national vaccination campaigns. Conclusion: The observed changes in group immunity and behavior in the population at greater risk of exposure to mpox seem unable to explain the waning of the mpox epidemic. A change in the profile of mpox patients might have contributed to the decline in cases.

Published
2024

37. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, de Vries, Rory D, Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, and de Vries, Rory D

Abstract

Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440). BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent boost while neutralization and T-cell responses were similar to mRNA-based primed participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent BA.5 boosted participants. Combined, our data further support the current use of monovalent vaccines based on circulating strains when vaccinating risk groups, as recently recommended by the WHO. We emphasize the importance of the continuous assessment of immune responses targeting circulating variants to guide future COVID-19 vaccination policies.

Published
2024

38. Primary Exposure to SARS-CoV-2 via Infection or Vaccination Determines Mucosal Antibody-Dependent ACE2 Binding Inhibition

Author

Fröberg, Janeri, Koomen, Vera J.C.H., Van Der Gaast-De Jongh, Christa E., Philipsen, Ria, Geurtsvankessel, Corine H., De Vries, Rory D., Baas, Marije C., Van Der Molen, Renate G., De Jonge, Marien I., Hilbrands, Luuk B., Huynen, Martijn A., Diavatopoulos, Dimitri A., Fröberg, Janeri, Koomen, Vera J.C.H., Van Der Gaast-De Jongh, Christa E., Philipsen, Ria, Geurtsvankessel, Corine H., De Vries, Rory D., Baas, Marije C., Van Der Molen, Renate G., De Jonge, Marien I., Hilbrands, Luuk B., Huynen, Martijn A., and Diavatopoulos, Dimitri A.

Abstract

Background: Mucosal antibodies play a critical role in preventing SARS-CoV-2 infections or reinfections by blocking the interaction of the receptor-binding domain (RBD) with the angiotensin-converting enzyme 2 (ACE2) receptor on the cell surface. In this study, we investigated the difference between the mucosal antibody response after primary infection and vaccination. Methods: We assessed longitudinal changes in the quantity and capacity of nasal antibodies to neutralize the interaction of RBD with the ACE2 receptor using the spike protein and RBD from ancestral SARS-CoV-2 (Wuhan-Hu-1), as well as the RBD from the Delta and Omicron variants. Results: Significantly higher mucosal IgA concentrations were detected postinfection vs postvaccination, while vaccination induced higher IgG concentrations. However, ACE2-inhibiting activity did not differ between the cohorts. Regarding whether IgA or IgG drove ACE2 inhibition, infection-induced binding inhibition was driven by both isotypes, while postvaccination binding inhibition was mainly driven by IgG. Conclusions: Our study provides new insights into the relationship between antibody isotypes and neutralization by using a sensitive and high-Throughput ACE2 binding inhibition assay. Key differences are highlighted between vaccination and infection at the mucosal level, showing that despite differences in the response quantity, postinfection and postvaccination ACE2 binding inhibition capacity did not differ.

Published
2024

39. Scenarios of future mpox outbreaks among men who have sex with men:a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022

Author

Shamier, Marc C., Zaeck, Luca M., Götz, Hannelore M., Vieyra, Bruno, Verstrepen, Babs E., Wijnans, Koen, Welkers, Matthijs R.A., Hoornenborg, Elske, van Cleef, Brigitte A.G.L., van Royen, Martin E., Jonas, Kai J., Koopmans, Marion P.G., de Vries, Rory D., van de Vijver, David A.M.C., GeurtsvanKessel, Corine H., Shamier, Marc C., Zaeck, Luca M., Götz, Hannelore M., Vieyra, Bruno, Verstrepen, Babs E., Wijnans, Koen, Welkers, Matthijs R.A., Hoornenborg, Elske, van Cleef, Brigitte A.G.L., van Royen, Martin E., Jonas, Kai J., Koopmans, Marion P.G., de Vries, Rory D., van de Vijver, David A.M.C., and GeurtsvanKessel, Corine H.

Abstract

Background: Following the 2022–2023 mpox outbreak, crucial knowledge gaps exist regarding orthopoxvirus-specific immunity in risk groups and its impact on future outbreaks. Aim: We combined cross-sectional seroprevalence studies in two cities in the Netherlands with mathematical modelling to evaluate scenarios of future mpox outbreaks among men who have sex with men (MSM). Methods: Serum samples were obtained from 1,065 MSM attending Centres for Sexual Health (CSH) in Rotterdam or Amsterdam following the peak of the Dutch mpox outbreak and the introduction of vaccination. For MSM visiting the Rotterdam CSH, sera were linked to epidemiological and vaccination data. An in-house developed ELISA was used to detect vaccinia virus (VACV)-specific IgG. These observations were combined with published data on serial interval and vaccine effectiveness to inform a stochastic transmission model that estimates the risk of future mpox outbreaks.Results: The seroprevalence of VACV-specific antibodies was 45.4% and 47.1% in Rotterdam and Amsterdam, respectively. Transmission modelling showed that the impact of risk group vaccination on the original outbreak was likely small. However, assuming different scenarios, the number of mpox cases in a future outbreak would be markedly reduced because of vaccination. Simultaneously, the current level of immunity alone may not prevent future outbreaks. Maintaining a short time-to-diagnosis is a key component of any strategy to prevent new outbreaks. Conclusion: Our findings indicate a reduced likelihood of large future mpox outbreaks among MSM in the Netherlands under current conditions, but emphasise the importance of maintaining population immunity, diagnostic capacities and disease awareness.

Published
2024

40. Rational attenuation of canine distemper virus (CDV) to develop a morbillivirus animal model that mimics measles in humans

Author

Schmitz, Katharina S., Rennick, Linda J., Tilston-Lunel, Natasha L., Comvalius, Anouskha D., Laksono, Brigitta M., Geers, Daryl, van Run, Peter, de Vries, Rory D., de Swart, Rik L., Duprex, W. Paul, Schmitz, Katharina S., Rennick, Linda J., Tilston-Lunel, Natasha L., Comvalius, Anouskha D., Laksono, Brigitta M., Geers, Daryl, van Run, Peter, de Vries, Rory D., de Swart, Rik L., and Duprex, W. Paul

Abstract

Morbilliviruses are members of the family Paramyxoviridae and are known for their ability to cause systemic disease in a variety of mammalian hosts. The prototypic morbillivirus, measles virus (MeV), infects humans and still causes morbidity and mortality in unvaccinated children and young adults. Experimental infection studies in non-human primates have contributed to the understanding of measles pathogenesis. However, ethical restrictions call for the development of new animal models. Canine distemper virus (CDV) infects a wide range of animals, including ferrets, and its pathogenesis shares many features with measles. However, wild-type CDV infection is almost always lethal, while MeV infection is usually self-limiting. Here, we made five recombinant CDVs, predicted to be attenuated, and compared their pathogenesis to the non-attenuated recombinant CDV in a ferret model. Three viruses were insufficiently attenuated based on clinical signs, fatality, and systemic infection, while one virus was too attenuated. The last candidate virus caused a self-limiting infection associated with transient viremia and viral dissemination to all lymphoid tissues, was shed transiently from the upper respiratory tract, and did not result in acute neurological signs. Additionally, an in-depth phenotyping of the infected white blood cells showed lower infection percentages in all lymphocyte subsets when compared to the non-attenuated CDV. In conclusion, infection models using this candidate virus mimic measles and can be used to study pathogenesis-related questions and to test interventions for morbilliviruses in a natural host species.IMPORTANCEMorbilliviruses are transmitted via the respiratory route but cause systemic disease. The viruses use two cellular receptors to infect myeloid, lymphoid, and epithelial cells. Measles virus (MeV) remains an important cause of morbidity and mortality in humans, requiring animal models to study pathogenesis or intervention strategies. Experimen

Published
2024

41. Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments

Author

Schmitz, Katharina S., Handrejk, Kim, Liepina, Lelde, Bauer, Lisa, Haas, Griffin D., van Puijfelik, Fabienne, Veldhuis Kroeze, Edwin J. B., Riekstina, Marta, Strautmanis, Jurgis, Cao, Huyen, Verdijk, Robert M., Geurtsvankessel, Corine H., van Boheemen, Sander, van Riel, Debby, Lee, Benhur, Porotto, Matteo, de Swart, Rik L., de Vries, Rory D., Schmitz, Katharina S., Handrejk, Kim, Liepina, Lelde, Bauer, Lisa, Haas, Griffin D., van Puijfelik, Fabienne, Veldhuis Kroeze, Edwin J. B., Riekstina, Marta, Strautmanis, Jurgis, Cao, Huyen, Verdijk, Robert M., Geurtsvankessel, Corine H., van Boheemen, Sander, van Riel, Debby, Lee, Benhur, Porotto, Matteo, de Swart, Rik L., and de Vries, Rory D.

Abstract

Subacute sclerosing panencephalitis (SSPE) is a rare but fatal late neurological complication of measles, caused by persistent measles virus (MeV) infection of the central nervous system. There are no drugs approved for the treatment of SSPE. Here, we followed the clinical progression of a 5-year-old SSPE patient after treatment with the nucleoside analog remdesivir, conducted a post-mortem evaluation of the patient’s brain, and characterized the MeV detected in the brain. The quality of life of the patient transiently improved after the first two courses of remdesivir, but a third course had no further clinical effect, and the patient eventually succumbed to his condition. Post-mortem evaluation of the brain displayed histopathological changes including loss of neurons and demyelination paired with abundant presence of MeV RNA-positive cells throughout the brain. Next-generation sequencing of RNA isolated from the brain revealed a complete MeV genome with mutations that are typically detected in SSPE, characterized by a hypermutated M gene. Additional mutations were detected in the polymerase (L) gene, which were not associated with resistance to remdesivir. Functional characterization showed that mutations in the F gene led to a hyperfusogenic phenotype predominantly mediated by N465I. Additionally, recombinant wild-type-based MeV with the SSPE-F gene or the F gene with the N465I mutation was no longer lymphotropic but instead efficiently disseminated in neural cultures. Altogether, this case encourages further investigation of remdesivir as a potential treatment of SSPE and highlights the necessity to functionally understand SSPE-causing MeV.

Published
2024

42. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., and Rokx, Casper

Subjects
Immune response -- Evaluation -- Comparative analysis, HIV patients -- Drug therapy, Biological sciences
Abstract

Background Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations this is unknown. In this study we set out to investigate, for the vaccines currently approved in the Netherlands, the immunogenicity and reactogenicity of SARS-CoV-2 vaccinations in PLWH. Methods and findings We conducted a prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S, and Ad26.COV2.S vaccines in adult PLWH without prior COVID-19, and compared to HIV-negative controls. The primary endpoint was the anti-spike SARS-CoV-2 IgG response after mRNA vaccination. Secondary endpoints included the serological response after vector vaccination, anti-SARS-CoV-2 T-cell response, and reactogenicity. Between 14 February and 7 September 2021, 1,154 PLWH (median age 53 [IQR 44-60] years, 85.5% male) and 440 controls (median age 43 [IQR 33-53] years, 28.6% male) were included in the final analysis. Of the PLWH, 884 received BNT162b2, 100 received mRNA-1273, 150 received ChAdOx1-S, and 20 received Ad26.COV2.S. In the group of PLWH, 99% were on antiretroviral therapy, 97.7% were virally suppressed, and the median CD4+ T-cell count was 710 cells/[mu]L (IQR 520-913). Of the controls, 247 received mRNA-1273, 94 received BNT162b2, 26 received ChAdOx1-S, and 73 received Ad26.COV2.S. After mRNA vaccination, geometric mean antibody concentration was 1,418 BAU/mL in PLWH (95% CI 1322-1523), and after adjustment for age, sex, and vaccine type, HIV status remained associated with a decreased response (0.607, 95% CI 0.508-0.725, p 300 BAU/mL, whilst in PLWH this response rate was 93.6%. In PLWH vaccinated with mRNA-based vaccines, higher antibody responses were predicted by CD4+ T-cell count 250-500 cells/[mu]L (2.845, 95% CI 1.876-4.314, p 500 cells/[mu]L (2.936, 95% CI 1.961-4.394, p 50 copies/mL was associated with a reduced response (0.454, 95% CI 0.286-0.720, p = 0.001). Increased IFN-[gamma], CD4+ T-cell, and CD8+ T-cell responses were observed after stimulation with SARS-CoV-2 spike peptides in ELISpot and activation-induced marker assays, comparable to controls. Reactogenicity was generally mild, without vaccine-related serious adverse events. Due to the control of vaccine provision by the Dutch National Institute for Public Health and the Environment, there were some differences between vaccine groups in the age, sex, and CD4+ T-cell counts of recipients. Conclusions After vaccination with BNT162b2 or mRNA-1273, anti-spike SARS-CoV-2 antibody levels were reduced in PLWH compared to HIV-negative controls. To reach and maintain the same serological responses as HIV-negative controls, additional vaccinations are probably required. Trial registration The trial was registered in the Netherlands Trial Register (NL9214). https://www.trialregister.nl/trial/9214., Author(s): Kathryn S. Hensley 1, Marlou J. Jongkees 1, Daryl Geers 2, Corine H. GeurtsvanKessel 2, Yvonne M. Mueller 3, Virgil A. S. H. Dalm 3,4, Grigorios Papageorgiou 5, Hanka [...]

Published
2022
Full Text
View/download PDF

43. Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up

Author

Hoek, Rogier A. S., primary, Liu, Siqi, additional, GeurtsvanKessel, Corine H., additional, Verschuuren, Erik A. M., additional, Vonk, Judith M., additional, Hellemons, Merel E., additional, Kool, Mirjam, additional, Wijbenga, Nynke, additional, Bogers, Susanne, additional, Scherbeijn, Sandra, additional, Rugebregt, Sharona, additional, van Gemert, Johanna P., additional, Steenhuis, Willie N., additional, Niesters, Hubert G. M., additional, van Baarle, Debbie, additional, de Vries, Rory D., additional, and Van Leer Buter, Coretta, additional

Published
2024
Full Text
View/download PDF

45. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.

Author

van Leeuwen, Leanne P. M., Grobben, Marloes, GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank L., van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A. S. H.

Subjects
BOOSTER vaccines, COVID-19 vaccines, IMMUNE response, SARS-CoV-2 Omicron variant, COMMON variable immunodeficiency
Abstract

Purpose: Previous studies have demonstrated that the majority of patients with an inborn error of immunity (IEI) develop a spike (S)-specific IgG antibody and Tcell response after two doses of the mRNA-1273 COVID-19 vaccine, but little is known about the response to a booster vaccination. We studied the immune responses 8 weeks after booster vaccination with mRNA-based COVID-19 vaccines in 171 IEI patients. Moreover, we evaluated the clinical outcomes in these patients one year after the start of the Dutch COVID-19 vaccination campaign. Methods: This study was embedded in a large prospective multicenter study investigating the immunogenicity of COVID-19 mRNA-based vaccines in IEI (VACOPID study). Blood samples were taken from 244 participants 8 weeks after booster vaccination. These participants included 171 IEI patients (X-linked agammaglobulinemia (XLA;N=11), combined immunodeficiency (CID;N=4), common variable immunodeficiency (CVID;N=45), isolated or undefined antibody deficiencies (N=108) and phagocyte defects (N=3)) and 73 controls. SARS-CoV-2-specific IgG titers, neutralizing antibodies, and T-cell responses were evaluated. One year after the start of the COVID-19 vaccination program, 334 study participants (239 IEI patients and 95 controls) completed a questionnaire to supplement their clinical data focusing on SARS-CoV-2 infections. Results: After booster vaccination, S-specific IgG titers increased in all COVID-19 naive IEI cohorts and controls, when compared to titers at 6 months after the priming regimen. The fold-increases did not differ between controls and IEI cohorts. SARS-CoV-2-specific T-cell responses also increased equally in all cohorts after booster vaccination compared to 6 months after the priming regimen. Most SARS-CoV-2 infections during the study period occurred in the period when the Omicron variant had become dominant. The clinical course of these infections was mild, although IEI patients experienced more frequent fever and dyspnea compared to controls and their symptoms persisted longer. Conclusion: Our study demonstrates that mRNA-based booster vaccination induces robust recall of memory B-cell and T-cell responses in most IEI patients. One-year clinical follow-up demonstrated that SARS-CoV-2 infections in IEI patients were mild. Given our results, we support booster campaigns with newer variant-specific COVID-19 booster vaccines to IEI patients with milder phenotypes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara–Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial

Author

de Vries, Rory D., Altenburg, Arwen F., Nieuwkoop, Nella J., de Bruin, Erwin, van Trierum, Stella E., Pronk, Mark R., Lamers, Mart M., Richard, Mathilde, Nieuwenhuijse, David F., Koopmans, Marion P. G., Kreijtz, Joost H. C. M., Fouchier, Ron A. M., Osterhaus, Albert D. M. E., Sutter, Gerd, and Rimmelzwaan, Guus F.

Published
2018

49. Primary Exposure to SARS-CoV-2 via Infection or Vaccination Determines Mucosal Antibody-Dependent ACE2 Binding Inhibition

Author

Fröberg, Janeri, primary, Koomen, Vera J C H, additional, van der Gaast-de Jongh, Christa E, additional, Philipsen, Ria, additional, GeurtsvanKessel, Corine H, additional, de Vries, Rory D, additional, Baas, Marije C, additional, van der Molen, Renate G, additional, de Jonge, Marien I, additional, Hilbrands, Luuk B, additional, Huynen, Martijn A, additional, and Diavatopoulos, Dimitri A, additional

Published
2023
Full Text
View/download PDF

50. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients

Author

Malahe, S. Reshwan K., primary, Hartog, Yvette den, additional, Rietdijk, Wim J.R., additional, van Baarle, Debbie, additional, de Kuiper, Ronella, additional, Reijerkerk, Derek, additional, Ras, Alicia M., additional, Geers, Daryl, additional, Diavatopoulos, Dimitri A., additional, Messchendorp, A. Lianne, additional, van der Molen, Renate G., additional, Remmerswaal, Ester B.M., additional, Bemelman, Frederike J., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Sanders, Jan-Stephan, additional, GeurtsvanKessel, Corine H., additional, Kho, Marcia M.L., additional, de Vries, Rory D., additional, Reinders, Marlies E.J., additional, Baan, Carla C., additional, Abrahams, Alferso C., additional, Baas, Marije C., additional, Mattheussens, Wouter B., additional, Philipsen, Ria H.L.A., additional, Bouwmans, Pim, additional, Hemmelder, Marc H., additional, ten Dam, Marc A.G.J., additional, Gommers, Lennert, additional, Mourik, Djenolan van, additional, Bogers, Susanne, additional, van Dijk, Laura L.A., additional, Standaar, Dorien, additional, der Heiden, Marieke van, additional, Adema, Yvonne M.R., additional, Boer-Verschragen, Marieken J., additional, Rots, Nynke, additional, and de Vries, Aiko P.J., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results